

Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

NCT07099157

Status	RECRUITING
Phase	Phase 4
Sponsor	Peking University Third Hospital
Enrollment	140 participants

Key Eligibility Criteria

Inclusion (7)

- Age ≥18 years, regardless of gender;
- Signed Informed Consent Form;
- Female subjects must not plan for pregnancy or oocyte donation from screening until 1 week after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include:
 - Barrier methods: Condom or barrier cap (diaphragm or cervical cap);
 - Intrauterine device (IUD) or intrauterine system (IUS);
- ... and 2 more (see full listing online)

Exclusion (6)

- Allergy to brivudine, famciclovir, or penciclovir;
- Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine);
- Cancer patients currently undergoing chemotherapy;
- Pregnant or lactating women;
- Parkinson's disease;
- ... and 1 more (see full listing online)

Locations (4 total)

Peking University Third Hospital, Beijing, China
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
Peking University First Hospital, Beijing, China
... and 1 more locations